Introduction
Methods
Results
Study | Year | Patients treated | Radionuclide used | Outcome | Toxicity |
---|---|---|---|---|---|
Kaemmerer et al. [21] | 2009 | 1 | 90Y-DOTATOC (2 cycles) | CR after surgery | Only mild transient hematologic toxicity |
Stoeltzing et al. [34] | 2010 | 1 | 90Y-DOTATOC (2 cycles) | CR after 1 year from surgery | Not reported |
Ezzidin et al. [22] | 2012 | 1 | 177Lu-DOTATATE (3 cycles) | Inoperable PAN-NET became eligible for surgery achieving a complete local remission for 22 months | Minor transient leukopenia (Grade 1) |
Barber et al. [28] | 2012 | 5 (4) | 177Lu-DOTATATE (1–4 cycles) | 3 scintigraphic PR; 4 radiological PR and 1SD. 1 patient affected by PanNET became eligible for surgery with a reduction in Ki67 from 10–15% to 5%. | Not reported |
Van Vliet et al. [23] | 2015 | 29 | 177Lu-DOTATATE (3–4 cycles) | 9/29 patients became amenable for surgery and had an increase in PFS vs. control group (69 vs. 49 months) | No patients showed delayed toxicity |
Partelli et al. [16] | 2018 | 23 | 177Lu/90Y-DOTATATE (20/3 pt.) | • No pancreatic fistula development in RLT patients. • Longer PFS in RLT patients with R0 resection. | Only 1 patient had hematologic toxicity and stopped RLT |
Da Silva et al. [24] | 2018 | 1 | 177Lu-DOTATATE | Patient became eligible for surgery and was tumor-free after 3-year follow up | No RLT-induced toxicity reported |
Zanata et al. [25] | 2021 | 1 | 90Y-DOTATOC | Patient became eligible for surgery and was tumor-free after 108 months follow up. Disease downstaging from stage IV to stage I. | Not reported |
Parghane et al. [26] | 2021 | 57 (32) | 177Lu-DOTATATE | 6/32 PanNETs became resectable after RLT. Primary tumors and liver metastasis decreased in size. | Not reported |
Opalinska et al. [27] | 2021 | 9 (6) | 177Lu/90Y-DOTATATE | Median primary tumor size decreased by 1.6 cm after RLT, with no differences between Pan-NETs and other GEP-NETs. 4/9 patients became resectable after RLT and in 2 a radical surgery was achieved. Liver metastases became undetectable in 2 patients. | No myelotoxicity or nephrotoxicity found |
Minczeles et al. [29] | 2022 | 49 | 177Lu-DOTATATE | Patients with neoadjuvant RLT followed by surgery had a longer PFS and OS than those who performed only RLT. A downstaging was found in the 38% of patients with baseline tumor-vessel involvement | 47% of patients had transient hematologic toxicity. G3 liver toxicity was found in 1 patient |